1. Molecular pathways: exploiting tumor-specific molecular defects in DNA repair pathways for precision cancer therapy.

    Clinical Cancer Research 20(23):5882 (2014) PMID 25451105

    Disabling mutations in genome maintenance and DNA repair pathways are frequently observed in cancer. These DNA repair defects represent genetic aberrations that are specific to cancer cells and not present in healthy tissues. It is thought that these molecular defects produce a "mutator phenotyp...
  2. Molecular pathways: exploiting tumor-specific molecular defects in DNA repair pathways for precision cancer therapy.

    Clinical Cancer Research 20(23):5882 (2014) PMID 25451105

    Disabling mutations in genome maintenance and DNA repair pathways are frequently observed in cancer. These DNA repair defects represent genetic aberrations that are specific to cancer cells and not present in healthy tissues. It is thought that these molecular defects produce a "mutator phenotyp...
  3. Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches.

    Trends in Genetics 30(8):326 (2014) PMID 25017190

    Defects in DNA repair pathways enable cancer cells to accumulate genomic alterations that contribute to their aggressive phenotype. However, tumors rely on residual DNA repair capacities to survive the damage induced by genotoxic stress. This dichotomy might explain why only isolated DNA repair ...
  4. Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches.

    Trends in Genetics 30(8):326 (2014) PMID 25017190

    Defects in DNA repair pathways enable cancer cells to accumulate genomic alterations that contribute to their aggressive phenotype. However, tumors rely on residual DNA repair capacities to survive the damage induced by genotoxic stress. This dichotomy might explain why only isolated DNA repair ...
  5. Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches.

    Trends in Genetics 30(8):326 (2014) PMID 25017190

    Defects in DNA repair pathways enable cancer cells to accumulate genomic alterations that contribute to their aggressive phenotype. However, tumors rely on residual DNA repair capacities to survive the damage induced by genotoxic stress. This dichotomy might explain why only isolated DNA repair ...
  6. Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches.

    Trends in Genetics 30(8):326 (2014) PMID 25017190

    Defects in DNA repair pathways enable cancer cells to accumulate genomic alterations that contribute to their aggressive phenotype. However, tumors rely on residual DNA repair capacities to survive the damage induced by genotoxic stress. This dichotomy might explain why only isolated DNA repair ...
  7. A functional cancer genomics screen identifies a druggable synthetic lethal interaction between MSH3 and PRKDC.

    Cancer Discovery 4(5):592 (2014) PMID 24556366

    Here, we use a large-scale cell line-based approach to identify cancer cell-specific mutations that are associated with DNA-dependent protein kinase catalytic subunit (DNA-PKcs) dependence. For this purpose, we profiled the mutational landscape across 1,319 cancer-associated genes of 67 distinct...
  8. Inferring primary tumor sites from mutation spectra: a meta-analysis of histology-specific aberrations in cancer-derived cell lines.

    Human Molecular Genetics 23(6):1527 (2014) PMID 24163242

    Next-generation sequencing technologies have led to profound characterization of mutation spectra for several cancer types. Hence, we sought to systematically compare genomic aberrations between primary tumors and cancer lines. For this, we compiled publically available sequencing data of 1651 g...
  9. Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer.

    Cancer Discovery 4(2):246 (2014) PMID 24302556

    The 8p12 locus (containing the FGFR1 tyrosine kinase gene) is frequently amplified in squamous cell lung cancer. However, it is currently unknown which of the 8p12-amplified tumors are also sensitive to fibroblast growth factor receptor (FGFR) inhibition. We found that, in contrast with other re...
  10. Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches

    Trends in Genetics (2013)

    • Tumor cells display entity-specific signatures of DNA repair pathway alterations. • HR defects are associated with DNA-PK- and PARP1-dependence. ...
  11. A framework for identification of actionable cancer genome dependencies in small cell lung cancer.

    PNAS 109(42):17034 (2012) PMID 23035247 PMCID PMC3479457

    Small cell lung cancer (SCLC) accounts for about 15% of all lung cancers. The prognosis of SCLC patients is devastating and no biologically targeted therapeutics are active in this tumor type. To develop a framework for development of specific SCLC-targeted drugs we conducted a combined genomic ...